Do analysts recommend MDP or WEED?

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts prefer MDP or FRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Does the media prefer MDP or FRX?

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 1 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.75 beat Fennec Pharmaceuticals' score of 0.18 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medexus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fennec Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CPH or MDP?

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Cipher Pharmaceuticals and 1 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.75 beat Cipher Pharmaceuticals' score of 0.59 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cipher Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medexus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ACB or MDP?

Aurora Cannabis currently has a consensus target price of C$6.20, suggesting a potential upside of 15.46%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, research analysts clearly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ACB or MDP?

In the previous week, Aurora Cannabis had 4 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 5 mentions for Aurora Cannabis and 1 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.75 beat Aurora Cannabis' score of -1.09 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Negative Medexus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medexus Pharmaceuticals (MDP) Competitors

C$5.10 -0.13 (-2.49%)

As of 09/3/2026 04:00 PM Eastern

Compare

MDP vs. WEED, FRX, VGW, CPH, and ACB

Should you buy Medexus Pharmaceuticals stock or one of its competitors? Medexus Pharmaceuticals's main competitors and comparable companies include Canopy Growth (WEED), Fennec Pharmaceuticals (FRX), Valens GroWorks (VGW), Cipher Pharmaceuticals (CPH), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Medexus Pharmaceuticals compare to Canopy Growth?

Medexus Pharmaceuticals (TSE:MDP) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than Canopy Growth. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.76 beat Medexus Pharmaceuticals' score of 0.75 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Medexus Pharmaceuticals	Positive
Canopy Growth	Positive

Medexus Pharmaceuticals has a beta of 0.53682, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.634762, suggesting that its share price is 63% more volatile than the broader market.

3.5% of Medexus Pharmaceuticals shares are held by institutional investors. Comparatively, 4.5% of Canopy Growth shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Medexus Pharmaceuticals has higher earnings, but lower revenue than Canopy Growth. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$103.30M	1.55	C$3.26M	-C$0.07	N/A
Canopy Growth	C$293.63M	2.07	-C$1.05B	-C$0.67	N/A

Medexus Pharmaceuticals has a net margin of -2.32% compared to Canopy Growth's net margin of -73.95%. Medexus Pharmaceuticals' return on equity of -4.72% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%
Canopy Growth	-73.95%	-29.85%	-3.83%

Summary

Canopy Growth beats Medexus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Fennec Pharmaceuticals?

Medexus Pharmaceuticals (TSE:MDP) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

3.5% of Medexus Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.2% of Fennec Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medexus Pharmaceuticals has higher revenue and earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$103.30M	1.55	C$3.26M	-C$0.07	N/A
Fennec Pharmaceuticals	C$59.22M	10.24	-C$800.44K	-C$0.12	N/A

Medexus Pharmaceuticals has a beta of 0.53682, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.548856, suggesting that its stock price is 255% more volatile than the broader market.

Medexus Pharmaceuticals has a net margin of -2.32% compared to Fennec Pharmaceuticals' net margin of -6.21%. Medexus Pharmaceuticals' return on equity of -4.72% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 1 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.75 beat Fennec Pharmaceuticals' score of 0.18 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medexus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fennec Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fennec Pharmaceuticals beats Medexus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Valens GroWorks?

Medexus Pharmaceuticals (TSE:MDP) and Valens GroWorks (CVE:VGW) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than Valens GroWorks. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for Valens GroWorks. Medexus Pharmaceuticals' average media sentiment score of 0.75 beat Valens GroWorks' score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Medexus Pharmaceuticals	Positive
Valens GroWorks	Neutral

Medexus Pharmaceuticals has higher revenue and earnings than Valens GroWorks. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Valens GroWorks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$103.30M	1.55	C$3.26M	-C$0.07	N/A
Valens GroWorks	C$27.50M	13.96	-C$22.41M	-C$0.18	N/A

3.5% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valens GroWorks has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -2.32%. Valens GroWorks' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%
Valens GroWorks	N/A	N/A	N/A

Summary

Medexus Pharmaceuticals beats Valens GroWorks on 8 of the 12 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.5% of Medexus Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has a beta of 1.153789, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.53682, indicating that its stock price is 46% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to Medexus Pharmaceuticals' net margin of -2.32%. Cipher Pharmaceuticals' return on equity of 22.74% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%

Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$49.62M	7.37	C$11.41M	C$1.12	12.85
Medexus Pharmaceuticals	C$103.30M	1.55	C$3.26M	-C$0.07	N/A

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, suggesting a potential upside of 18.14%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cipher Pharmaceuticals is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Cipher Pharmaceuticals and 1 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.75 beat Cipher Pharmaceuticals' score of 0.59 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medexus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Aurora Cannabis currently has a consensus target price of C$6.20, suggesting a potential upside of 15.46%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, research analysts clearly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Medexus Pharmaceuticals has a net margin of -2.32% compared to Aurora Cannabis' net margin of -9.53%. Medexus Pharmaceuticals' return on equity of -4.72% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-9.53%	-5.21%	-1.87%
Medexus Pharmaceuticals	-2.32%	-4.72%	4.89%

Aurora Cannabis has a beta of 0.246838, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.53682, indicating that its stock price is 46% less volatile than the broader market.

Medexus Pharmaceuticals has lower revenue, but higher earnings than Aurora Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$314.07M	1.06	-C$44.16M	-C$1.94	N/A
Medexus Pharmaceuticals	C$103.30M	1.55	C$3.26M	-C$0.07	N/A

In the previous week, Aurora Cannabis had 4 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 5 mentions for Aurora Cannabis and 1 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.75 beat Aurora Cannabis' score of -1.09 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Negative
Medexus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.1% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 3.5% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Medexus Pharmaceuticals beats Aurora Cannabis on 9 of the 16 factors compared between the two stocks.

Get Medexus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDP vs. The Competition

Export

Metric	Medexus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$164.36M	C$12.25B	C$7.26B	C$12.57B
Dividend Yield	N/A	2.59%	2.53%	6.25%
P/E Ratio	-72.86	787.27	273.29	39.47
Price / Sales	1.55	754.88	623.67	9.82
Price / Cash	N/A	94.80	77.82	82.29
Price / Book	3.38	12.33	12.92	4.71
Net Income	C$3.26M	C$2.82B	C$3.47B	C$299.09M
7 Day Performance	0.79%	2.60%	0.60%	-0.31%
1 Month Performance	2.20%	6.96%	5.72%	3.12%
1 Year Performance	67.21%	9.45%	25.33%	28.73%

Medexus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDP Medexus Pharmaceuticals	N/A	C$5.10 -2.5%	N/A	+66.1%	C$164.36M	C$103.30M	N/A	98
WEED Canopy Growth	2.0205 of 5 stars	C$1.39 -2.8%	C$1.88 +34.9%	-29.7%	C$624.53M	C$293.63M	N/A	2,700
FRX Fennec Pharmaceuticals	0.1132 of 5 stars	C$17.00 flat	N/A	+40.0%	C$596.14M	C$59.22M	N/A	10	Gap Down
VGW Valens GroWorks	N/A	C$3.10 +1.6%	N/A	+0.0%	C$383.88M	C$27.50M	N/A	N/A
CPH Cipher Pharmaceuticals	1.5698 of 5 stars	C$14.16 +0.4%	C$17.00 +20.1%	-9.2%	C$359.88M	C$49.62M	12.64	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MDP) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. WEED, FRX, VGW, CPH, and ACB

How does Medexus Pharmaceuticals compare to Canopy Growth?

Summary

How does Medexus Pharmaceuticals compare to Fennec Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to Valens GroWorks?

Summary

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Summary

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. WEED, FRX, VGW, CPH, and ACB

How does Medexus Pharmaceuticals compare to Canopy Growth?

Does the media prefer MDP or WEED?

Which has more volatility & risk, MDP or WEED?

Do insiders & institutionals believe in MDP or WEED?

Do analysts recommend MDP or WEED?

Which has better earnings & valuation, MDP or WEED?

Is MDP or WEED more profitable?

Summary

How does Medexus Pharmaceuticals compare to Fennec Pharmaceuticals?

Do institutionals & insiders hold more shares of MDP or FRX?

Which has preferable earnings & valuation, MDP or FRX?

Which has more volatility and risk, MDP or FRX?

Is MDP or FRX more profitable?

Do analysts prefer MDP or FRX?

Does the media prefer MDP or FRX?

Summary

How does Medexus Pharmaceuticals compare to Valens GroWorks?

Does the media refer more to MDP or VGW?

Which has stronger earnings and valuation, MDP or VGW?

Do insiders & institutionals believe in MDP or VGW?

Is MDP or VGW more profitable?

Summary

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Do institutionals and insiders hold more shares of CPH or MDP?

Which has more risk and volatility, CPH or MDP?

Is CPH or MDP more profitable?

Which has higher valuation and earnings, CPH or MDP?

Do analysts prefer CPH or MDP?

Does the media refer more to CPH or MDP?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Do analysts prefer ACB or MDP?

Is ACB or MDP more profitable?

Which has more volatility and risk, ACB or MDP?

Which has stronger earnings & valuation, ACB or MDP?

Does the media refer more to ACB or MDP?

Do institutionals & insiders hold more shares of ACB or MDP?

Summary

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools